Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Biogen (BIIB)
Barclays Initiates Biogen(BIIB.US) With Hold Rating, Announces Target Price $190
RBC Cuts Price Target on Biogen to $269 From $292, Keeps Outperform Rating
Biogen Is Maintained at Neutral by UBS
Biogen Analyst Ratings
UBS Initiates Biogen(BIIB.US) With Hold Rating, Announces Target Price $202
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating
Baird Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $225 to $300
Maintaining Hold on Biogen Amid Uncertain Efficacy and Competitive SLE Market
Buy Rating Affirmed for Biogen on Promising Phase 3 Results and Strategic Development Plans for Lupus Drug Dapi
Biogen Is Maintained at Neutral by Wedbush
Biogen Analyst Ratings
Wedbush Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $205
Wedbush Trims Price Target on Biogen to $205 From $210, Keeps Neutral Rating
Biogen Analyst Ratings
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $292
RBC Capital Keeps Their Buy Rating on Biogen (BIIB)
Biogen Analyst Ratings